In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:

• First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding risk
• First-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding risk
• First-line systemic treatment for a patient with Child-Pugh B liver function
• Second-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumab
• Management of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitor

Presenters:

Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
https://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.